6 October 2016First patients dosed in Phase 2a proof-of-concept study with rectal formulation of TopiVert’s TOP1288 in moderate to severe ulcerative colitis
London, UK, 6 October 2016: TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and eye, announced today that the first patients have been dosed in its Phase 2a proof-of-concept study to evaluate the safety, tolerability and efficacy of a rectal formulation of TOP1288 in symptomatic ulcerative colitis (UC) patients with moderate to severe disease activity.
21 September 2016Wilson Therapeutics announces support of the Annual Event Big Wow to raise awareness of Wilson Disease
Wilson Therapeutics AB (publ) today announced its sponsorship of the second annual Big Walk on Wilson’s (Big Wow). The event will take place on October 1, 2016, in 24 cities across North America to increase awareness of Wilson Disease and raise funds for the Wilson Disease Association.
16 September 2016World’s first Transcatheter Tricuspid Valve Repair (TTVR) has been successfully achieved without use of TEE and General Anesthesia
World’s first Transcatheter Tricuspid Valve Repair (TTVR) has been successfully achieved without use of TEE and General Anesthesia in feasibility study of 4Tech TriCinch™ at San Raffaele Hospital, Milano, Italy.
12 September 2016Avitide, Inc., secures Series D Financing from Mithril to expand Affinity Resin Dicovery Platform and Resin Manufacturing Operations
Lebanon, New Hampshire – September 12th, 2016 – Avitide, Inc., the leader in the discovery, manufacture, and supply of novel affinity purification solutions for the biopharmaceutical industry, closed its Series D financing. Mithril Capital Management, LLC led the financing round.
12 September 2016
(Oxford, UK, 12 September 2016) Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune disease, today notes that it has been ranked fourth overall in the 16th annual Sunday Times Hiscox Tech Track 100. Immunocore appears in the league table for the second time, rising up the rank from ninth place in 2015.